IPP Bureau
Syngene biologics facility to be operational for US, European customers from mid-year
By IPP Bureau - March 17, 2024
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Cipla appoints Venkata Sai Mungara as Global Head – Supply Chain
By IPP Bureau - March 17, 2024
Mungara has over 25+ years of experience in the supply chain domain
Sumitomo Pharma announces availability of ORGOVYX in Canada
By IPP Bureau - March 17, 2024
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Evonik Vland Biotech JV commences operations
By IPP Bureau - March 16, 2024
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery
By IPP Bureau - March 16, 2024
More than 10,000 scientific publications containing EUDRAGIT
Bayer and Aignostics to collaborate on next generation precision oncology
By IPP Bureau - March 16, 2024
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility
By IPP Bureau - March 16, 2024
The company is confident of addressing the concern raised by the USFDA
Indranil Sen, CFO, Biocon resigned
By IPP Bureau - March 16, 2024
Sen spent a decade with Biocon and held various key roles,
Abbott India appointed Swati Dalal as MD
By IPP Bureau - March 16, 2024
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Zydus launches generic version of Olaparib ‘IBYRA’ in India
By IPP Bureau - March 14, 2024
The drug will target specific genetic mutations prevalent in certain types of cancers
Cureskin secures US$ 20 million in Series B funding
By IPP Bureau - March 14, 2024
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Zydus receives USFDA final approval for chlorpromazine hydrochloride injection
By IPP Bureau - March 14, 2024
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9
By IPP Bureau - March 14, 2024
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
